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Stlmmary 
The absence of readily manipulable experimental systems to study the cytotoxic T lymphocyte 
(CTL) response against hepatitis B virus (HBV) antigens has thus far precluded a definitive 
demonstration of the role played by this response in the pathogenesis of liver cell injury and 
viral clearance during HBV infection. To circumvent the problem that HBV infection of human 
cells in vitro for production of stimulator/target systems for CTL analysis is not feasible, a panel 
of 22 overlapping synthetic peptides covering the entire amino acid sequence of the HBV core 
(HBcAg) and e (HBeAg) antigens were used to induce and to analyze the HBV nucleocapsid-specific 
CTL response in nine patients with acute hepatitis B, six patients with chronic active hepatitis 
B, and eight normal controls. By using this approach, we have identified an HLA-A2-restricted 
CTL epitope, located within the NH2-terminal region of the HBV core molecule, which is 
shared with the e antigen and is readily recognized by peripheral blood mononudear cells from 
patients with self-limited acute hepatitis B but less efficiently in chronic HBV infection. Our 
study provides the first direct evidence of HLA class I-restricted T cell cytotoxicity against HBV 
in humans. Furthermore, the different response in HBV-infected subjects who successfully clear 
the virus (acute patients) in comparison with patients who do not succeed (chronic patients) 
suggests a pathogenetic role for this CTL activity in the clearance of HBV infection. 
H 
epatitis B virus (HBV) 1 infection is a worldwide health 
problem with an estimate of about 250 million people 
carrying the virus who can develop chronic hepatitis, liver 
cirrhosis, and ultimately hepatocellular carcinoma. As in other 
infections with noncytopathic  viruses, a HLA class I-restricted 
cytotoxic T cell response to endogenously synthesized HBV 
proteins is believed to be the major determinant of infected 
cell clearance (1-4). 
It is well known that CTLs recognize short amino acid 
(AA) sequences derived from the intracellular processing of 
viral antigens in association with HLA class I molecules on 
the surface of the infected cells (5-10).  Since HBV does not 
efficiently infect human cells in vitro, the use of short syn- 
thetic peptides mimicking the processed antigen fragments 
can be a rational strategy to stimulate the HBV-specific CTL 
response (11-15). Based on this concept, a panel of short pep- 
1  Abbreviations used in this paper: AA, amino acid; AVH-B, acute hepatitis 
type B; HBcAg, Hepatitis B virus core antigen; HBV, hepatitis B virus; 
SGPT, serum glutamic pyruvic transaminase. 
tides representing the entire HBV nucleocapsid region were 
synthesized and used for CTL analysis. 
Our results demonstrate that HBV nucleocapsid-specific 
CTL are present in the peripheral blood of patients with acute 
HBV infection and that this response in the context of HLA-A2 
haplotype is focused on a CTL epitope included within the 
11-27 sequence of the HBV core antigen (HBcAg). The ob- 
servation that patients with acute and chronic HBV infec- 
tion express different levels of CTL response may reflect im- 
mune events of pathogenetic relevance with respect to viral 
clearance and disease evolution. 
Materials  and Methods 
Patients.  Nine patients with acute hepatitis type B (AVH-B), 
six patients with chronic HBV infection, and eight healthy sub- 
jects were studied. The diagnosis  of  AVH-B was based  on the finding 
of elevated  values of serum glutamic pyruvic transaminase (SGPT) 
(at least 10 times the upper limit of the normal), associated with 
the detection of IgM antibodies against HBc.Ag  in the serum and 
the recent onset of  jaundice and other typical symptoms of acute 
hepatitis. All patients with acute HBV infection recovered com- 
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clearance of hepatitis B surface antigen from the serum. The diag- 
nosis  of chronic hepatitis type B was based on biochemical and 
histological findings (16); SGPT levels ranged from 60 to 355 (normal 
<35) IU/liter. All patients were antibody negative to HIV, hepa- 
titis C, and 6 viruses. 
Antigens.  rHBcAg was obtained from bacterial extracts of Esch- 
erichia coil K12 strain HB101 harboring the recombinant plasmid 
carrying the HBcAg coding gene as previously described (17). 
A panel of 22 overlapping synthetic Peptides (10-20 AA long) 
corresponding to the entire sequence of the core- and pre-core re- 
gion-encoded polypeptides (subtype ayw) was kindly provided by 
Cytel (La Jolla, CA) or purchased from Multiple Peptide System 
(La Jolla, CA). AA sequences of the Peptides used in this study 
and their location within the HBV core and e molecules are illus- 
trated in Fig.  1 A. 
Induction ofHBV-specific CTL.  PBMC were isolated from fresh 
heparinized blood by Ficoll-Hypaque density gradient centrifuga- 
tion and resuspended at 4  x  10  ~ cells/m1 (24 wells/phte) in RPMI 
1640 containing 10% human AB serum. Cells were stimulated ei- 
ther with rHBcAg (1/~g/ml) or with four distinct peptide pools 
(MIX 1, MIX 2, MIX 3, MIX 4) each one consisting of five to 
six synthetic peptides (Fig.  1 A). Individual peptides were used 
at the concentration of 5/~g/ml. Fresh medium containing 10% 
FCS and 20 U/ml of rIL-2 was added on days 3 and 5 of culture 
and the cytotoxicity assay was performed on day 7. 
CTtotox/a  ~  Assay~  After 7 d of culture, stimulated PBMC were 
tested for their cytolytic activity against autologous macrophages 
or EBV-transformed  B (EBV-B) cells as targets: (a) incubated over- 
night in medium alone; (b) incubated overnight with rHBcAg; (c) 
pulsed for 2 h with the different peptide mixtures; or (d) pulsed 
for 2 h with individual peptides.  Target cells labeled with 100/zCi 
of S:Cr (NaS~CrO4; Amersham International, Buckinghamshire, 
England) for I h at 37~  were cocultured with activated PBMC 
at an E/T ratio of 50 or 100:1 in 96-well round-bottomed plates 
(similar  results were obtained at both E/T ratios). The amount 
of StCr released in the culture supematants was evaluated after 4 h 
of incubation and the percentage of S~Cr release was calculated as 
follows: 100x [(cpm E -  cpm SR)/(cpm MR -  cpm SK)]; where 
E  indicates  the  S~Cr activity present in  the  supernatant  of ex- 
perimental culture, and SK and MK represent the spontaneous and 
maximum amounts of SlCr released by target cells cultured in 
medium alone or in the presence of 10% Triton X, respectively. 
Restriction Experiments.  After 7 d of culture, MIX 4--activated 
CTL were tested against autologous or allogeneic, partially HLA- 
matched macrophages, or EBV-B cells as targets either prepulsed 
with peptide 11-27 or incubated in medium alone. The cytolytic 
activity was measured 4 h later as above described. 
Results and Discussion 
Four pools of synthetic peptides covering the entire HBV 
core and e molecules (Fig. 1 A) were initially used to stimu- 
late PMBC of a patient with AVH-B in an attempt to induce 
nudeocapsid-specific CTL. After 7 d of stimulation either 
with the peptide pools or with a recombinant preparation 
of core antigen, cytolytic activity was tested in a 4-h cyto- 
toxicity assay against autologous macrophage targets pre-pulsed 
either with the pools of peptides or with exogenous core an- 
tigen (Fig. 1 B). No detectable cytolytic activity was induced 
by MIX  1,  2,  and 3 containing also previously identified 
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Figure 1.  Activation  of HBV-specific 
CTL by PBMC stimulation with syn- 
thetic peptides. (A) Synthetic peptide 
sequences (with indication of the dis- 
tinct peptide mixtures used for CTL 
analysis), HBcAg and HBeAg mole- 
cules, and  HBV  core open  reading 
frame. (B) Cytolytic activity of PBMC 
stimulated for 7 d with the peptide mix- 
tures against autologous targets pre- 
pulsed either with the same stimulatoty 
mixture or with exogenous  Hl~g. (C) 
Lysis of autologous target cells pre- 
pulsed with the individual peptides in- 
cluded in MIX 4, by MIX 4-stimulated 
PBMC. MIX 4 or peptide 11-27-pulsed 
target cells were never lysed  by PBMC 
stimulated with MIX 1, MIX 2, MIX 
3, or e~ogenous  HBcAg (not shown). 
The E/T ratio used was always 100:1. 
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Figure 2.  HLA restriction of peptide 11-27 recognition. PBMC from five patients with AVH-B were stimulated for 7 d with MIX 4, and their 
cytolytic activity was tested against autologous or allogeneic, partiaUy HLA-matched macrophages, or EBV-B cell lines as targets (E/T ratio of 50:1) 
either pre-pulsed with peptide 11-27 (1~'/7~) or incubated in medium alone (~).  The HLA haplotype of each patient (top of each panel) and the 
HLA molecules shared by patients and target cells (bottom of each panel) are indicated. 
HBcAg helper epitopes (18), whereas PBMC stimulated with 
MIX 4 expressed significant cytotoxicity against target cells 
pulsed with the same mixture. Interestingly, PBMC stimu- 
lated with the whole core molecule could not recognize MIX 
4-pulsed targets and, conversely,  PBMC activated by MIX 
4 did not lyse macrophages incubated with exogenous HBcAg 
(data not  shown).  These findings suggest  that the AA se- 
quence within MIX 4 responsible for CTL activation is not 
generated by the intracellular processing of exogenous core 
protein. 
The  specific peptide  11-27  was then identified  as being 
responsible for the induction of the cytotoxic activity by MIX 
4 (Fig.  1 C). The single-letter code AA sequence of this pep- 
tide is ATVELLSFLPSDFFPSV, which is conserved among 
the major subtypes of HBV. It is noteworthy that this pep- 
tide overlaps with a previously identified sequence containing 
an immunodominant helper epitope (AA sequence 1-20) rec- 
ognized by approximately 70% of patients with acute HBV 
infection (18). These cytotoxic and helper epitopes are con- 
tiguous but certainly distinct  since peptide  1-20  (included 
in MIX1) did not induce a cytotoxic response, whereas the 
cytotoxic peptide 11-27 was totally unable to stimulate PBMC 
proliferation in any of the acute patients studied (not shown). 
The nature of the effector cytotoxic cells induced by pep- 
tide stimulation was then investigated by restriction experi- 
ments designed to define the specific restriction element in- 
volved in the recognition of peptide 11-27. MIX 4-activated 
PBMC did not lyse allogeneic, peptide 11-27-pulsed EBV-B 
cells  sharing the HLA class  II molecules  with the PBMC 
donor. In contrast,  the cytolytic activity was selectively de- 
tected against target cells expressing the HLA-A2 molecule 
(Fig. 2 A).  Moreover,  CTL activity was inhibited by anti- 
CD8 but not anti-CD4  antibodies  (data not  shown).  The 
observation that peptide 11-27 is recognized by CTL in as- 
sociation with HLA-A2 antigens suggests that this peptide 
likely mimics a specific CTL epitope generated by the intra- 
cellular processing of endogenously synthesized HBcAg  in 
infected cells since this processing pathway mainly leads to 
association of the processed antigen with HLA class I mole- 
cules  (19-22). 
This possibility  is further supported by separate  experi- 
ments, to be reported in detail elsewhere (23),  showing the 
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Figure 3.  CTL activity of PBMC from 
HLA-A2-positive acute  and chronic HBV- 
infected patients and normal subjects after 
stimulation with MIX 4. MIX 4-activated 
PBMC  from  nine HLA-A2 patients with 
AVH-B (top) were tested against autologous 
macrophages  (E/T ratio 50:1) incubated in 
medium alone, or pre-pulsed with MIX 4, 
or with the immunogenic peptide 11-27, or 
with an irrelevant control Peptide (pep. 147- 
161).  All  patients  were  repeatedly tested 
during the course of illness and a representa- 
tive experiment for each subject is illustrated. 
Patient no. 7 was not tested against autolo- 
gous macrophages  pulsed with MIX 4 and 
peptide  147-161  (NT,  not  tested).  MIX 
4-stimulated PBMC from six HLA-A2 sub- 
jects with chronic HBV infection (m~/d/e) and 
eight HLA-A2 healthy subjects (bottom) were 
tested for their cytotoxic activity (E/T ratio 
50:1) against autologous targets pulsed with 
the same peptide mixture used for induction. 
By using the individual peptides, cytotoxicity 
against MIX  4  in patient  4  (middle)  yeas 
shown to be directed against peptide 11-27 
(not shown). Roman numbers (middle) desig- 
nate  distinct  experiments  performed  at 
different time points in individual patients. 
Patients 1, 2, 5, and 6 (middle) were HBeAg 
and HBV-DNA positive, patient 3 was anti- 
HBe positive and HBV-DNA negative, and 
patient  4  was  anti-HBe  and  HBV-DNA 
positive. 
capacity of peptide-induced CTL to recognize endogenous 
HBcAg encoded by recombinant vaccinia and Epstein Barr- 
based plasmid  vectors in autologous EBV-B cells. 
To assess the immunodominance in the HLA-A2 haplo- 
type of the CTL epitope contained in peptide 11-27, eight 
additional subjects with stir-limited AVH-B, six patients with 
chronic active hepatitis t3, and eight healthy subjects without 
evidence of previous exposure to HBV (all HLA-A2 positive) 
were repeatedly tested. All the acute patients serially studied 
(every 7-10  d) during the symptomatic and the recovery 
periods of disease efficiently recognized autologous target ceils 
pulsed with peptide 11-27 as well as with MIX 4 (Fig. 3, 
top).  Restriction  experiments  performed  with  MIX 
4-stimulated PBMC from four of them confirmed that CTL 
recognition of peptide  11-27 is HLA-A2 restricted (Fig. 2, 
B-E). Patient to patient variations in the pattern of response 
to peptide 11-27 were observed during the course of the ill- 
ness. The cytolytic activity was generally detectable during 
the symptomatic phase when SGPT values were high (Fig. 
4, A and B); in some patients the response was long lasting, 
being still detectable when SGFI' levels had already become 
normal (Fig. 4, C and D); in other subjects the lytic activity 
became undetectable 2 or 3 wk after the transaminase peak 
when SGPT levels were still slightly altered (Fig. 4 B). The 
lack of a constant association between CTL activity and SGPT 
levels could be explained considering that the peripheral blood 
compartment only partially  reflects immune events taking 
place in the liver at the site of antigen synthesis and cellular 
injury (24). 
Five of the six chronic patients  (each one tested two to 
four times, following the same experimental protocol used 
for the acute patients), did not show cytolytic activity against 
autologous targets pulsed with peptide 11-27 (contained in 
MIX 4), while one patient displayed detectable, though very 
low levels of cytotoxicity against the relevant peptide sequence 
(Fig. 3, middle, patient 4). The lyric activity against peptide 
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Figure 4.  Serial  determinations of the cytolytic activity expressed by PBMC from four representative patients with AVH-B during the course of 
acute infection. SGPT levels assayed  at the same time points are also illustrated. PBMC were stimulated with MIX 4 and then tested against peptide 
11-27-pulsed autologous target cells. 
11-27 was not present  in normal  HLA-A2-positive control 
subjects (Fig.  3, bottom). This shows that  the cytolytic ac- 
tivity displayed by HBV patients is not due to in vitro priming 
and that peptide stimulation selectively expands a specific T 
cell population  pre-primed  in vivo by HBV infection. 
In conclusion, our results indicate a clear association be  o 
tween the CTL response to core peptide 11-27 and acute HBV 
infection  in  patients  who  succeed  in  clearing  the  virus. 
Whether the absent or weak CTL response to the core epi- 
tope identified in the present  study among the population 
of chronic patients actually reflects an immune defect respon- 
sible for the inability to clear the virus or a preferential intra- 
hepatic sequestration in chronic disease remains to be further 
investigated using intrahepatic T cells. The experimental ap- 
proach defined in this study will hopefully provide the ap- 
propriate tools to answer these central issues in HBV patho- 
genesis. Finally,  the finding that the NH2-terminal portion 
of the core molecule contains two contiguous and probably 
overlapping immunodominant  epitopes for helper and cyto- 
toxic T cells might be valuable for future preventive and ther- 
apeutic strategies against  HBV infection. 
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